NIKKEI 225
39,727.91 +386.37 (+0.98%) HANG SENG
17,825.85 +109.38 (+0.62%) CRUDE OIL
82.21 +0.47 (+0.57%) GOLD FUTURES
2,333.60 -3.00 (-0.13%) DOW
39,164.06 +36.26 (+0.09%) Bitcoin GBP
48,752.29 +522.40 (+1.08%)
MBOT Jul 2024 5.000 put
| Previous close | 3.9000 |
| Open | 3.9000 |
| Bid | 2.1000 |
| Ask | 5.1000 |
| Strike | 5.00 |
| Expiry date | 2024-07-19 |
| Day's range | 3.9000 - 3.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 15 |
GlobeNewswireMicrobot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial
Following FDA Approval to Commence the Clinical Trial, an Official Site Initiation Has Taken Place as Preparation for Patient Enrollment Advances Multiple Robotic Systems Already Received by the Site to Allow Inventory Readiness in Support of Trial BRAINTREE, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced its agreement with Brigham and Women’s Hospital (BWH), a leading academic medical center located in Boston, Massachusetts, to serve as one of the sites
- GlobeNewswire
Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial
The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was deliveredBRAINTREE, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announces that Brigham and Women’s Hospital (BWH), a leading academic medical center located in Boston, Massachusetts, will participate as a clinical trial site for the pivotal human clinical trial as part of its Investigational Device Exemption (“IDE”) application for its LIBER
- GlobeNewswire
Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
HINGHAM, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,566,669 shares of the Company’s common stock at a purchase price of $1.50 per share of common stock . In addition, in a concurrent private placement, the Company has issued unregistered series F preferred investment options. The series F preferred investm
